Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of eribulin in patients with recurrent glioblastoma (ENIGMA)

Next Previous
Trial Profile

Phase II trial of eribulin in patients with recurrent glioblastoma (ENIGMA)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2018

At a glance

  • Drugs Eribulin (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Acronyms ENIGMA

    • Most Recent Events

    • 20 Jan 2018 Status changed from not yet recruiting to recruiting.
    • 26 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top